Skip to main content

Table 3 Peptide reactivity, immune response rate and clinical response.

From: High Immune Response Rates and Decreased Frequencies of Regulatory T Cells in Metastatic Renal Cell Carcinoma Patients after Tumor Cell Vaccination

  Peptide reactivity (number of tested peptides)   
Patient ID Prevaccination Postvaccination TTP (wks) Survival (wks)
MR-1 a10/15b 7/13 (2)c 7 31
MR-2 12/16 15/17 (11) 23 79
MR-4 13/14 15/17 (7) 35 68
MR-5d 3/14 15/15 (11) 7 76
MR-6d 8/16 3/17 (1) 6 18
MR-7d 2/16 5/15 (5) 28 84
MR-9 3/18 4/17 (1) 39 79
MR-10 16/19 13/19 (0) 23 55
MR-11 7/17 7/15 (3) SD (7)e 17
MR-13 13/18 13/18 (4) 33 104 (alive)
MR-14 9/19 17/19 (9) 35 107
MR-15 6/19 15/19 (8) SD (131)e 151 (alive)
Immune response rate (%) 100f 100 (75)f   
Clinical response (wks)    25.5g 77.5g
  1. TTP, time to progression; SD, stable disease.
  2. aNumbers of peptides to which reactivity was observed (>10 spots above background).
  3. bNumbers of peptides tested (survivin, cyclin D1, adipophilin, c-MET, vimentin, PRUNE2, VEGF, NY-ESO, MMP7, TYMS, IGF-BP3, RGS-5, CA IX, CP,TIF-1, ORMDL3, CLIC1, ELAC2 and PIG-10).
  4. cNumbers of peptides (in bold) to which a greater-than-two-fold increase after versus before vaccination was detectable.
  5. dShort protocol of vaccination starting with the middle dose of 107 vaccine cells.
  6. eSD (7) and SD (131) indicate stable disease at wks 7 and 131, respectively.
  7. fPatients reacting to more than one peptide in %.
  8. gMedian PD and median survival in weeks.